#H2 Receptor Antagonist Market
Text
QY Research Medical published a comprehensive research on H2 Receptor Antagonist Market, which provides a business strategies, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.
0 notes
Text
Outlook on the Evolving GERD & NERD Treatment Market
Market Overview –
Over the course of the forecast period, 2023–2030, the Americas GERD & NERD therapy market is anticipated to increase USD 4.99 at a CAGR of 6.20%.
The GERD & NERD treatment market is evolving to meet the needs of individuals suffering from gastroesophageal reflux disease (GERD) and non-erosive reflux disease (NERD). With a focus on NERD reflux treatment, pharmaceutical companies are developing medications to alleviate symptoms like heartburn and acid regurgitation. As awareness grows, there's a rising demand for effective therapies, driving market growth and innovation.
The GERD (Gastroesophageal Reflux Disease) and NERD (Non-Erosive Reflux Disease) treatment market addresses medical interventions aimed at managing and alleviating symptoms associated with these gastrointestinal disorders. GERD involves chronic acid reflux, causing heartburn, regurgitation, and other symptoms, while NERD presents similar symptoms without visible esophageal damage. This market encompasses various treatment options, including medications, lifestyle modifications, and surgical interventions, tailored to the severity and underlying causes of reflux.
A key driver of the GERD & NERD treatment market is the high prevalence of these disorders globally, attributed to factors such as obesity, poor dietary habits, smoking, and genetic predisposition. As awareness of GERD & NERD increases among both patients and healthcare providers, there is a growing demand for effective treatment options to alleviate symptoms and improve quality of life.
Advancements in medical technology and pharmaceuticals have led to the development of novel treatment approaches for GERD & NERD. Proton pump inhibitors (PPIs), H2 receptor antagonists, antacids, and prokinetic agents are commonly used medications to reduce gastric acid production and alleviate symptoms. Additionally, minimally invasive procedures like endoscopic therapies and surgical interventions offer alternatives for patients with refractory symptoms or complications.
The COVID-19 pandemic has impacted the GERD & NERD treatment market, with disruptions in healthcare services, changes in patient behavior, and challenges in accessing specialized care. However, telemedicine and remote consultations have emerged as valuable tools in managing GERD & NERD, enabling patients to receive timely advice and prescriptions from healthcare providers.
Segmentation –
Americas GERD & NERD treatment market is segmented on the basis of drug class, dosage form, and end user. On the basis of drug class, the market is segmented into antacids (acid neutralizers), proton pump inhibitors, H2 receptor blocker, prokinetic agents, antidepressants, calcium channel blockers, and others. Proton pump inhibitors are further segmented into esomeprazole, omeprazole, pantoprazole, lansoprazole, dexlansoprazole, rabeprazole, and others. H2 receptor blocker is further segmented into ranitidine, famotidine, cimetidine, nizatidine, and others. Prokinetic agents are further segmented into domperidone, metoclopramide, itopride, prucalopride, cisapride, benzamide, mosapride, erythromycin, and others. Based on the dosage form, it is segmented into solid and liquid. On the basis of the end user, it is segmented into hospitals & clinics, research centers, and others.
Regional Analysis –
The GERD (Gastroesophageal Reflux Disease) and NERD (Non-Erosive Reflux Disease) treatment market varies regionally due to differences in disease prevalence, treatment guidelines, and healthcare infrastructure. In developed regions like North America and Europe, where there is a higher incidence of GERD and NERD, the market for acid-suppressive medications, lifestyle modifications, and minimally invasive procedures is well-established, with a focus on symptom relief and disease management. Conversely, in developing regions with limited access to gastroenterology specialists and diagnostic tools, such as parts of Africa and Asia-Pacific, the market for GERD and NERD treatment is still evolving, with challenges related to underdiagnosis and undertreatment. Moreover, cultural dietary habits and healthcare-seeking behaviors influence patient adherence to treatment regimens and healthcare utilization patterns across different regions. As awareness of GERD and NERD risks grows globally, there is a growing opportunity for market expansion through education, early intervention, and investment in gastroenterology services to improve outcomes for patients with acid reflux disorders worldwide.
Key Players –
GERD & NERD treatment major players in the Americas include AstraZeneca Plc (U.K), Boston Scientific Corporation (U.S.), Cempra Inc. (U.S.), Eisai Co., Ltd. (Japan), EndoGastric Solutions Inc. (U.S.), EndoStim Inc. (U.S.), GlaxoSmithKline Plc (U.K), Ironwood Pharmaceuticals, Inc. (U.S.), Jeil pharmaceutical Co. Ltd. (South Korea), Johnson & Johnson (U.S.), Mederi Therapeutics Inc. (U.S.), Medigus Ltd. (Israel), Medtronic Inc. (U.S.), Merck & CO., Inc. (U.S.), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Takeda Pharmaceutical Company Limited (Japan), Teva Pharmaceuticals Industries Limited (Israel), Torax Medical (U.S.), Valeant Pharmaceuticals International, Inc. (Canada), Carbon Medical technologies (U.S.), Allegiant health (U.S.), Tya pharmaceuticals (U.S.), and Sanofi (France).
Related Reports –
Pain Patch
Electronic Trial Master File Systems
Neurology Devices
Medical Payment Fraud Detection
For more information visit at MarketResearchFuture
#GERD & NERD Treatment#GERD & NERD Treatment Size#GERD & NERD Treatment Share#GERD & NERD Treatment Growth#GERD & NERD Treatment Trends
0 notes
Text
Peptic Ulcer Drugs Market Emerging Growth Analysis, Future Demand and Business Opportunities 2032
The Peptic Ulcer Drugs market is a vital segment of the pharmaceutical industry, dedicated to addressing the debilitating condition of peptic ulcers. Peptic ulcers are painful sores that form on the lining of the stomach, small intestine, or esophagus due to factors like Helicobacter pylori infection or long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs). As of 2033, this market is experiencing notable growth driven by a rising global prevalence of peptic ulcers and the development of more effective treatment options.
One of the key drivers of the Peptic Ulcer Drugs market's growth is the increasing recognition of the role of Helicobacter pylori in ulcer formation. Advances in diagnostic techniques have improved the identification of this bacterium as a primary cause of peptic ulcers, leading to targeted antibiotic therapies. The market has witnessed the development of combination drug regimens that effectively eradicate H. pylori infections, reducing the recurrence of ulcers and improving patient outcomes.
Furthermore, the market is benefiting from the emergence of novel drug classes and formulations. Proton pump inhibitors (PPIs) and H2-receptor antagonists remain essential for managing ulcer symptoms, but researchers are continuously exploring new pharmacological approaches. These innovations aim to enhance the effectiveness of ulcer treatment while minimizing side effects, offering patients a broader range of therapeutic options.
As pharmaceutical companies invest in research and development, and healthcare providers emphasize early diagnosis and effective treatment, the Peptic Ulcer Drugs market is poised to continue its growth trajectory. It plays a pivotal role in alleviating the suffering of individuals with peptic ulcers, contributing to better quality of life and reduced healthcare costs associated with ulcer-related complications.
For More Info@ https://www.openpr.com/news/2926017/global-peptic-ulcer-drugs-market-2023-2033-increasing-nsaid
In conclusion, the Peptic Ulcer Drugs market is a crucial player in the fight against peptic ulcers, offering hope and relief to millions of affected individuals worldwide. With ongoing advancements in both diagnosis and treatment, this market is set to remain at the forefront of digestive health, providing innovative solutions to improve the well-being of those afflicted by this painful condition.
0 notes
Text
0 notes
Text
Global Gastritis Treatment Market Is Estimated To Witness High Growth Owing To Increasing Prevalence of Gastritis
The global Gastritis Treatment Market is estimated to be valued at USD 162.2 million in 2021 and is expected to exhibit a CAGR of 4% over the forecast period 2022-2029, as highlighted in a new report published by Coherent Market Insights.
A) Market Overview:
Gastritis is a condition characterized by the inflammation of the lining of the stomach. It can be caused by various factors such as infection, excessive alcohol consumption, prolonged use of non-steroidal anti-inflammatory drugs (NSAIDs), and autoimmune diseases. The Gastritis Treatment Market products includes pharmaceutical drugs, proton pump inhibitors (PPIs), H2 receptor antagonists, antacids, and antibiotics.
The need for gastritis treatment products arises due to the increasing prevalence of gastritis worldwide. According to the World Gastroenterology Organisation (WGO), gastritis affects approximately 50% of the global population. The rising incidence of risk factors such as H. pylori infection, unhealthy lifestyle habits, and the growing aging population contribute to the increasing demand for gastritis treatment products.
B) Market Key Trends:
One key trend in the gastritis treatment market is the increasing adoption of combination therapy. Combination therapy involves the simultaneous use of two or more drugs to achieve a synergistic effect in treating gastritis. This approach helps in improving treatment outcomes and reducing the risk of drug resistance. For instance, a combination therapy of proton pump inhibitors and antibiotics is often prescribed for the eradication of H. pylori infection. The use of combination therapy is expected to drive market growth during the forecast period.
Technological: The development of advanced diagnostic techniques such as endoscopy and molecular tests has improved the accuracy and efficiency of gastritis diagnosis, leading to better treatment outcomes.
D) Key Takeaways:
1: The global gastritis treatment market is expected to witness high growth, exhibiting a CAGR of 4% over the forecast period. This growth can be attributed to increasing prevalence of gastritis and the rising demand for treatment products. The market is driven by factors such as H. pylori infection, unhealthy lifestyle habits, and the growing aging population.
2: In terms of regional analysis, North America is expected to dominate the gastritis treatment market due to the high prevalence of gastritis in the region. Asia Pacific is anticipated to be the fastest-growing region, owing to the increasing healthcare expenditure and improving healthcare infrastructure in countries like India and China.
3: Key players operating in the global gastritis treatment market include Otsuka Indonesia PT, AstraZeneca PLC, Zydus Cadila Healthcare Limited, Novartis AG, and others. These companies focus on product development, partnerships, and collaborations to strengthen their market position.
In conclusion, the global gastritis treatment market is projected to grow significantly over the forecast period. Increasing prevalence of gastritis and the adoption of combination therapy are key trends driving market growth. Political initiatives, economic factors, changing social habits, and technological advancements further contribute to the expansion of the market. North America is expected to dominate the market, while Asia Pacific is anticipated to witness the highest growth. Key players in the market include Otsuka Indonesia PT, AstraZeneca PLC, Zydus Cadila Healthcare Limited, and Novartis AG, among others.
#Proton Pump Inhibitors#Gastritis Treatment Market#Gastritis Treatment Market Share#Gastritis Treatment Market Size#Gastritis Treatment Market Demand
0 notes
Text
0 notes
Text
0 notes
Text
0 notes
Text
0 notes
Text
GERD Drugs and Devices Market Demand Analysis, Statistics, Industry Growth Research Report till 2027
The Global GERD Drugs and Devices market Report offers extensive knowledge and information about the GERD Drugs and Devices market pertaining to market size, market share, growth influencing factors, opportunities, and current and emerging trends. The report is formulated with the updated and latest information of the GERD Drugs and Devices market further validated and verified by the industry experts and professionals. The report additionally sheds light on the emerging growth opportunities in the business sphere that are anticipated to bolster the growth of the market.
Gastroesophageal Reflux Disease is growing due to the intake of analgesics, smoking, decrease in the prevalence of Helicobacter pylori infection, consumption of certain types of food and drinks, high body mass index (BMI), family history of GERD, and limited physical activity. The growing incidence of the disease will drive the demand for the GERD drug and devices market.
The factors impacting the growth of the market are the rise in the trend of self-medication and increased awareness of GERD. Moreover, the constant occurrence of GERD disorders, as well as changes in lifestyle, are propelling the market demand. The expiration of the patent on most of the drugs is paving the way for new over the counter and generic drugs. The poor reimbursement of procedures and devices, low safety, and efficacy are restricting the adoption of the GERD drugs and devices market.
Click the link to get info@ https://www.emergenresearch.com/industry-report/gerd-drugs-and-devices-market
Some Key Highlights of Report
In November 2020, Sandoz Inc. announced it had shipped pantoprazole sodium to supply the hospitals for injection, 40 mg to Civica Rx. It is a part of a multiyear collaboration for the reduction in supply shortages with several other pipeline medicines.
H2 blockers are a group of drugs that reduces the amount of acid produced by the cell lining of the stomach. They are also known as histamine H2-receptor antagonists but are also known as H2 blockers. They include ranitidine, cimetidine, nizatidine, and famotidine, among others.
The MUSE or Medigus Ultrasonic Surgical Endostapler is an extensive endoscopic device that incorporates the latest technological advancement for the delivery of patient-friendly option for Transoral Fundoplication, the procedure intended for the treatment of GERD.
Overview of the TOC of the Report:
Introduction, Scope, and Overview
Opportunities, Risks, and Drivers
Competition landscape analysis with sales, revenue, and price
Extensive Profiling of the key competitors with the sales figures, revenue, and market share
Regional analysis with sales, revenue, and market share for each region for the forecast period
Country-wise analysis of the GERD Drugs and Devices market by type, application, and manufacturers
GERD Drugs and Devices Market Segmentation based on types
GERD Drugs and Devices Market segmentation based on applications
Historical and forecast estimation
Competitive Landscape:
Furthermore, the report includes an in-depth analysis of the competitive landscape. The segment covers a comprehensive overview of the company profiles along with product profiles, production capacities, products/services, pricing analysis, profit margins, and manufacturing process developments. The report also covers strategic business measures undertaken by the companies to gain substantial market share. The report provides insightful information about recent mergers and acquisitions, product launches, collaborations, joint ventures, partnerships, agreements, and government deals.
Key participants include Johnson & Johnson, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Pfizer Inc., Novartis AG, GlaxoSmithKline Plc, Merck & CO., Inc., Boston Scientific Corporation, Eisai Co., Ltd., and Ironwood Pharmaceuticals, Inc., among others.
For the purpose of this report, Emergen Research has segmented into the global GERD Drugs and Devices Market on the basis of route of administration, drug type, device type, and region:
Route Of Administration Outlook (Revenue, USD Billion; 2017-2027)
Oral
Parenteral
Drug Type Outlook (Revenue, USD Billion; 2017-2027)
H2 Receptor Antagonist
Proton Pump Inhibitor (PPIs)
Antacids
Device Type Outlook (Revenue, USD Billion; 2017-2027)
MUSE –Medigus Ultrasonic Surgical Endostapler
LINX Management System
Stretta Therapy
Bravo Reflux Testing System
Digitrapper reflux testing system
Others
Key takeaways of the Global GERD Drugs and Devices Market report:
The report sheds light on the fundamental GERD Drugs and Devices market drivers, restraints, opportunities, threats, and challenges.
It elaborates on the new, promising arenas in the leading GERD Drugs and Devices market regions.
It examines the latest research & development projects and technological innovations taking place in the key regional segments.
The research report reviews the regulatory framework for creating new opportunities in various regions of the GERD Drugs and Devices market
It focuses on the new revenue streams for the players in the emerging markets.
Furthermore, the report offers vital details about the rising revenue shares and the sizes of the key product segments.
Thank you for reading our report. Customization of the report is available. To know more, please connect with us, and our team will ensure the report is customized as per your requirements.
Take a Look at our Related Reports:
healthcare it market
https://www.google.bi/url?q=https://www.emergenresearch.com/industry-report/healthcare-it-market
coal tar market
https://www.google.bi/url?q=https://www.emergenresearch.com/industry-report/coal-tar-market
ir spectroscopy market
https://www.google.bi/url?q=https://www.emergenresearch.com/industry-report/ir-spectroscopy-market
eubiotics market
https://www.google.bi/url?q=https://www.emergenresearch.com/industry-report/eubiotics-market
nanotechnology market
https://www.google.bi/url?q=https://www.emergenresearch.com/industry-report/nanotechnology-market
ed-tech and smart classroom market
https://www.google.bi/url?q=https://www.emergenresearch.com/industry-report/ed-tech-and-smart-classroom-market
digital payment market
https://www.google.bi/url?q=https://www.emergenresearch.com/industry-report/digital-payment-market
signal conditioning modules market
https://www.google.bi/url?q=https://www.emergenresearch.com/industry-report/signal-conditioning-modules-market
About Us:
At Emergen Research, we believe in advancing with technology. We are a growing market research and strategy consulting company with an exhaustive knowledge base of cutting-edge and potentially market-disrupting technologies that are predicted to become more prevalent in the coming decade.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: [email protected]
Visit for More Insights: https://www.emergenresearch.com/insights
Explore Our Custom Intelligence services | Growth Consulting Services
0 notes
Text
Global H2 Receptor Antagonist Market research to Hold a High Potential for Growth by 2019-2029
The ~US$ 2.6 billion market for H2 receptor antagonist has been envisaged to witness lethargic growth prospects over the years to come., according to a recent research study of XploreMR. The research report for H2-receptor antagonists market elaborates the dynamics that are related to the growth and fragmented nature of the market. The market is expected to expand at a considerable rate, which can be majorly attributed to the growing incidence of gastroesophageal reflux disease (GERD) as well as the increasing adoption rate of H2-receptor antagonists.
Research shows that the growing adoption of proton-pump inhibitors is a major factor due to which the H2-receptor antagonists market is likely to witness sluggish growth over the forecast period. In terms of influencing factors, presence of generic OTC H2-receptor antagonists and prevalence of GERD and peptic ulcer population are the clear. A present, the disease trend observed around the world indicates that eastern countries are more prone to regurgitation-dominant GERD and western countries observe heartburn-dominant GERD.
Get Sample Copy of this Report @ https://www.xploremr.com/connectus/sample/3989
The H2-receptor antagonists market has not been experiencing considerable growth over the past few years owing to the availability of generic medications, growth in the number of local players, as well as the adverse effects associated with the consumption of H2-receptor antagonists. There are severe health risks associated with the consumption of H2-receptor antagonists, which include headaches, fatigue, abdominal pain, diarrhea, and drowsiness. The use of H2-receptor antagonists for patients with renal difficulties, hepatic impairment, or patients who are aged 50 years, can lead to adverse effects to the central nervous system. Drug interactions with the use of H2-receptor antagonists may go wrong at times, and a therapeutic increase in gastric pH is likely to disrupt the mechanism of drugs that require an acidic environment for dissolution.
Evolving Adoption Patterns, Driven by Strong Alternative Competitors
Consumer preference has changed for H2-receptor antagonists, which limits the market growth for H2-receptor antagonists. The market is already experiencing tough competition from other valuable alternatives, and present effects associated with the consumption of these drugs makes it even worse for manufacturers to label their products. Advisory labels for H2-receptor antagonists is mandatory, however, the present physical differences among consumers can lead to difficulties that they are not aware of.
The demand-side trends, which show increasing access to affordable generic versions of treatment, are indicating low spending for treatment, which is offsetting the increasing spending on branded drugs. The adoption of H2-receptor antagonists has changed over the years with the introduction of Zantac, which is considered to be the first billion-dollar drug to face growing competition from proton-pump inhibitors. There are other occasionally used alternative drug types available for cases, which include potassium-competitive acid blockers, antacids, and cytoprotective agents.
Request for Check Discount @ https://www.xploremr.com/connectus/check-discount/3989
Although the H2-receptor antagonists market is mature and highly competitive, most segments of the H2-receptor antagonists market are either saturated or nearing saturation. Extensive pricing competition among generic manufacturers facilitate a continuous demand growth, which is in relation to the adoption of H2-receptor antagonists. Most of the major players in the pharmaceutical industry are manufacturing proton-pump inhibitors.
The adoption and clinical benefits associated with proton-pump inhibitors are larger in number, hence, a smaller number of manufacturers are present in the H2-receptor antagonists market. Clinically better products with affordable pricing can still act as significant influencers for this H2-receptor antagonists market. In the face of global volatility, manufacturers gain profits due to the reliability, productivity, and awareness offered by loyal consumers.
Targeting countries for marketing H2-receptor antagonists is most important as the emergence and presence of generic manufacturers has led to a more competitive market structure. Moreover, entering a H2-receptor antagonists market with many local players providing drugs at a considerably low cost is a challenge for most of the global manufacturers.
Request Methodology of this Report @ https://www.xploremr.com/connectus/request-methodology/3989
At present, the global H2-receptor antagonists market is highly fragmented, with the presence of few global manufacturers and a large number of regional manufacturers. Some of the key H2-receptor antagonist manufacturers include Alembic Pharmaceuticals Ltd, Cipla Ltd., Torrent Pharmaceuticals Ltd., Sanofi S.A., Abbott, Glenmark Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., Cadila Healthcare Ltd, and GlaxoSmithKline Plc.
About us:
XploreMR is one of the world’s leading resellers of high-quality market research reports. We feature in-depth reports from some of the world’s most reputed market research companies and international organizations. We serve across a broad spectrum – from Fortune 500 to small and medium businesses. Our clients trust us for our unwavering focus onquality and affordability. We believe high price should not be a bottleneck for organizations looking to gain access to quality information.
Our team comprises an eclectic mix of experienced market research specialists, search engine specialists, web designers, online marketers, and business writers. The team is highly committed to going above and beyond, and serving the research needs of our clientele.
Contact us:
111 North Market Street, Suite 300,
San Jose, CA 95113, United States
Tel: +1-669-284-0108
E-mail: [email protected]
Website: www.xploremr.com
0 notes
Text
Global H2 Receptor Antagonist Market Vendor Landscape with SWOT Analysis 2020 to 2026
Global H2 Receptor Antagonist Market Vendor Landscape with SWOT Analysis 2020 to 2026
“Global H2 Receptor Antagonist Sales Market (Sales,Revenue and competitors Analysis of Major Market) from 2014-2026” the new research report published by kandjmarketresearch.com and it spreads across 105 Pages, with summarizing Top companies and supports with tables and figures.
The forecasts featured in the report have been derived using proven research methodologies and expectations. By…
View On WordPress
#H2 Receptor Antagonist#H2 Receptor Antagonist Market#H2 Receptor Antagonist Market Analysis#H2 Receptor Antagonist Market Growth#H2 Receptor Antagonist Market Price#H2 Receptor Antagonist Market Share#H2 Receptor Antagonist Market Size#H2 Receptor Antagonist Market Trends
0 notes
Text
Global H2 Receptor Antagonist Sales Market Report
ReportsnReports added Global H2 Receptor Antagonist Sales Market Research Report created by Report Consultant, which offers detailed insights, revenue details, and other information regarding the global market, and the various trends, drivers, restraints, opportunities, and market till 2028. Global H2 Receptor Antagonist Sales Market Report offers detailed information regarding the leading key players operating in the market, their financials, supply chain trends, technological innovations, key developments, apart from future strategies, acquisitions and mergers, and market footprint. Global H2 Receptor Antagonist Sales Market also provides a comparative analysis of the market dynamics pre and post Covid19 outbreak.
Request for FREE PDF Sample Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=4436594
0 notes
Text
Anaphylaxis Treatment Market, Size, Share 2021-2028
Market Overview
The Global Anaphylaxis Treatment Market is expected to grow at a high CAGR during the forecasting period (2021-2028).
Anaphylaxis is a severe allergic reaction to the venom, food, or medication. Mostly it is caused by a bee sting or eating foods that are known to cause allergies, such as peanuts or tree nuts. Some of the common causes of anaphylaxis include medication, peanuts, tree nuts, insect stings, fish, shellfish, and milk. Other causes may include exercise and latex.
The primary drug treatments for acute anaphylactic reactions are epinephrine and H1 antihistamines. As per the 2013 World Allergy Association update, 2015 Joint Task Force anaphylaxis update, and 2010 NIAID guidelines, epinephrine is the drug of choice for life-threatening reactions.
Download free sample: https://www.datamintelligence.com/download-sample/anaphylaxis-treatment-market
Market Dynamics
The global anaphylaxis treatment Market growth is driven by several factors such growing prevalence of allergies and their awareness among customers, and increasing advancement in the product with cost-effective solutions.
Growing cases of anaphylaxis and rising demand for self-administered drugs are driving the market growth.
Rise in patient pool suffering from allergies globally is a major factor driving the anaphylaxis treatment market. In the US and the UK, the incidence of anaphylaxis is 40–500 per million persons, mortality is estimated at 0.63–0.76 per million. In the US, up to 5% population suffers from this condition. The clinical databases such as PubMed have captured the growing prevalence of anaphylaxis.
As per a journal published on NCBI (National Center for Biotechnology Information) in 2017, up to 5% of the U.S. population suffered from the anaphylaxis condition. In addition, around 1% of total hospitalizations and 0.1% of emergency attendances for anaphylaxis would have fatal outcomes. Drugs are a major cause of fatal anaphylaxis in various countries, such as Australia, New Zealand, the U.K., Brazil, and the U.S. As per a journal published on NCBI, in year 2018, the lifetime prevalence of the anaphylaxis is estimated to be 0.05% – 2% in the U.S., and approx. 3% in the Europe. Overall, the fatality of anaphylaxis condition is relatively low across the globe.
Therefore, the growing incidence of anaphylaxis is likely to increase the high uptake of anaphylaxis treatment market.
COVID-19 Impact Analysis
The COVID-19 is affecting the global economy by directly affecting production and demand, by disturbing the supply chain and market disruption, and by its financial impact on firms and financial markets.
Lockdown regulations have been relaxed in most countries, but people are reluctant to visit doctors in person, due to the fear of spreading coronavirus (COVID-19). Thus, companies in the anaphylaxis treatment market are adopting telemedicine as individuals prefer remote healthcare services amidst the COVID-19 era. The demand for telehealth technology is expected to rise dramatically during the forecast period. Telemedicine apps are helping to expedite the process of quality medical care in the sphere of warts therapeutics.
Segment Analysis
– By Drug Class
· Adrenergic Agonists*
· Antihistamines
· H2 Receptor Antagonists
· Bronchodilators
· Corticosteroids
· Positive Inotropic Agents
· Vasopressors
Geographical Analysis
In terms of region, the global anaphylaxis treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
North America is Expected to Dominate the Global Anaphylaxis Treatment Market
North America accounted for the largest market share of the global anaphylaxis treatment Market in 2019, owing to the rise in patient pool suffering from the condition. In addition, awareness towards the allergic tests and fatalities due to various allergic condition are projected to boost the growth of the anaphylaxis treatment market in this region. Also, lifestyle changes, early diagnosis of specific allergies, and availability of anaphylaxis treatment are likely to boost the expansion of the anaphylaxis treatment market in North America. Some of the key players in the region are focusing on launching innovative products, including the generic version of epinephrine, for the anaphylaxis condition. This is projected to fuel market growth in in the region. Competitive Landscape
Some of the major players in global anaphylaxis treatment market includes ALK-Abelló A/S, Amneal Pharmaceuticals Inc, Adamis Pharmaceuticals Corporation, Kaleo Inc, Mylan N.V, Novartis International AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd., among others. The market players are involved in developing cost-effective and robust solutions to gain market share.
The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the anaphylaxis treatment market globally. For instance,
Teva Pharmaceutical Industries Ltd has developed an EpiPen which is a generic version of EpiPen Jr and approved by FDA in August 2019. The pen is developed using VIBEX device by Antares Pharma to prevent and provide aid against life-threatening, allergic emergencies including anaphylaxis or any allergic history in genes of patient. The dose of the EpiPen depends on the weight and fitness of the patient or as prescribed by the medical practitioners.
In June 2017, The FDA approved an epinephrine injector product called Symjepi, made by Adamis Pharmaceutical Corp. as the latest alternative to Mylan Pharmaceuticals' EpiPen for the treatment of severe allergic reactions. The product is a 0.3-mg prefilled syringe for the emergency treatment of allergic reactions, including anaphylaxis, for patients who weigh 30 kg (66 pounds) or more.
In July 2018, INSYS Therapeutics, Inc., a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced that its investigational epinephrine nasal spray showed promise in an early clinical trial as a potential needle-free, non-invasive and easy-to-use alternative to intramuscular injection for the treatment of anaphylaxis.
Overview:
Pfizer Inc. is an American pharmaceutical corporation headquartered in New York City. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology. Its products include the blockbuster drug Lipitor (atorvastatin), used to lower LDL blood cholesterol; Lyrica (pregabalin) for neuropathic pain and fibromyalgia; Diflucan (fluconazole), an oral antifungal medication; Zithromax (azithromycin), an antibiotic; Viagra (sildenafil) for erectile dysfunction; and Celebrex (also Celebra, celecoxib), an anti-inflammatory drug.
Products:
EpiPen® (epinephrine injection, USP) 0.3 mg Auto-Injectors
Key Developments:
In April 2012, Mylan Inc. and Pfizer Inc. announced that Meridian Medical Technologies, a Pfizer subsidiary, has entered into a settlement agreement with Teva that will resolve pending patent litigation related to its abbreviated new drug application (ANDA) for a generic epinephrine auto-injector.
View Full Report: https://www.datamintelligence.com/research-report/anaphylaxis-treatment-market
Enquiry Before Buying: https://www.datamintelligence.com/enquiry/anaphylaxis-treatment-market
About Us
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at DataM Intelligence
Email: [email protected]
Tel: +1 877 441 4866
Website: www.datamintelligence.com
0 notes
Link
The global Gastroesophageal Reflux Disease (GERD) therapeutics market size was valued at USD 5.66 billion in 2016 and by is estimated to be USD 4.34 billion by 2025, it is anticipated to observe a decrease in its revenue at a negative CAGR of -2.9%. Expiration of patented blockbuster drugs, which are indicated for the management of disorders of acid reflux is major restraining factors for this market.
With strong clinical pipelines and patent litigations, the market continues to experience significant changes. Proton pump inhibitors (PPI) and antagonists of histamine H2 receptor have the importance in current scenario of the market.
Upon loss of patent protection of formerly leading branded drugs, generic molecules with low-price can ingest the sales of the branded ones up to 90%. Rising number of companies being exposed to price scrutiny associated with shift in the focus of government on the promotion of consumer convenience will stimulate further reduction of drug prices. Although market turnover is affected by the expiration of major patents and the demand of drugs used to reduce acid, due to the increasing prevalence of heartburn, is anticipated to increase in the upcoming years.
0 notes
Text
Over Prescribing Proton Pump Inhibitors & a Glimpse on Its Side Effects-Juniper Publishers
JUNIPER PUBLISHERS-OPEN ACCESS JOURNAL OF DRUG DESIGNING & DEVELOPMENT
Introduction
Proton pump inhibitors are one of the most frequently prescribed classes of drug in the world because they combine a high level of efficacy with low toxicity. In 2006, expenditure on these drugs was £7bn globally [1] Yet studies consistently show that proton pump inhibitors are being overprescribed worldwide in both primary and secondary care [2]. Between 25% and 70% of patients taking these drugs have no appropriate indication. This means that, at the very least, £100m from the National Health Service (NHS) budget and almost £2bn worldwide is being spent unnecessarily on proton pump inhibitors each year.
The first generic proton pump inhibitor (omeprazole) was introduced in 2002 and now comprises more than four fifths of all prescriptions for proton pump inhibitors in India. In the five years since the introduction of omeprazole, prescriptions for proton pump inhibitors have doubled, although the reasons for this rise are not obvious [3]. Despite this substantial increase in drug usage, the decrease in price means that overall expenditure on proton pump inhibitors has been falling in recent years. Effective and less expensive alternative drugs, such as H2 receptor antagonists are available for many patients. Yet prescriptions for proton pump inhibitors have superseded those for all other acid inhibiting agents and now account for over 90% of the NHS drug budget for treating dyspepsia. Proton pump inhibitors cost more than other agents, which is partly why prescribing guidelines have been drafted in several countries. The National Institute for Health and Clinical Excellence (NICE) published its guidelines on proton pump inhibitors in 2000. Its recommendations for using these drugs particularly in the long term are relatively selective [4]. If prescriptions were restricted to the recommended indications, expenditure on proton pump inhibitors would be far less than 90% of the total dyspepsia drug budget.
Proton pump inhibitors have been a tremendous therapeutic advance. Especially in the long term, they have transformed the lives of patients with previously intractable symptoms of gastro-oesophageal reflux with its associated complications and they have also proved valuable for patients who are at risk of iatrogenic upper gastrointestinal pathology. A short term trial of a proton pump inhibitor is also a good option for treating a wide range of acid-peptic conditions. But the drugs are clearly being overused. Some people will point to their combination of superior efficacy and high safety as a justification for using them in preference to drugs such as H2 receptor antagonists. Yet, side effects should not be overlooked. An increase in the prevalence of pneumonia and Campylobacter enteritis is reported, as well as a doubling of the risk of infection with Clostridium difficile [5]. Acute interstitial nephritis and osteoporosis are unusual but recognised consequences of treatment with proton pump inhibitors [6]. Such effects are fortunately rare. The adverse effect of over prescription on drug budgets around the world is the real problem. Quite how to motivate doctors to follow guidelines is a matter of considerable importance.
Proton pump inhibitors & hypomagnesemia
Proton pump inhibitors (PPIs) were introduced to the market for peptic ulcer disease in 1989. Hypomagnesemia was reported for the first time in medical literature as a potential side effect of this class of drugs in 2006. The US Food and Drug Administration released a warning in 2011 about low serum magnesium levels associated with long-term use of PPIs. An analysis of the Food and Drug Administration's Adverse Event Reporting System shows that approximately 1% of patients experienced hypomagnesemia while on PPIs [7]. Symptoms include seizures, arrhythmias, hypotension, tetany, and death [8]. Despite the evidence, hypomagnesemia related to chronic PPI use was not addressed in the 2013 American College of Gastroenterology guidelines [9].
PPIs are widely used, both through prescription and over the counter, and are believed to be safe; however, one of the rare but serious complications is hypomagnesemia. It is well reported in nephrology journals [10]. However, the paucity in the internal medicine literature is amazing and prompted us to present this case. To our knowledge, there have been only 4 case reports of PPI-induced hypomagnesemia resulting in seizures [11]. Magnesium is excreted via renal and gastrointestinal routes. The prime culprit in PPI-induced hypomagnesemia is impaired intestinal absorption [12]. In patients with gastrointestinal mal absorption, H2 antagonists should be the first-line therapy, or if PPI use is essential, then the patient should be monitored closely for hypomagnesemia, especially for cardiac patients who might have a propensity for arrhythmia. There is a clear correlation between longterm use of PPI and hypomagnesemia, and clinicians need to be aware of it.
Proton pump inhibitors & in high risk cardiovascular subsets
Proton-pump inhibitors (PPIs) have been demonstrated to reduce rates of gastrointestinal events in patients requiring dual anti platelet therapy (DAPT). Data are limited regarding the efficacy and safety of PPIs in high-risk cardiovascular subsets after acute coronary syndrome or percutaneous coronary intervention. PPI therapy attenuates gastrointestinal bleeding risk without significant excess in major cardiovascular events in high-risk cardiovascular subsets, regardless of indication for DAPT. Future studies will be needed to clarify optimal gastro protective strategies for higher-intensity and longer durations of DAPT
Hypomagnesemic hypoparathyroidism may develop during long-term PPI therapy [1,2]. Patients can be asymptomaticorpresentwithlife-threateningarrhythmiasand neuromuscular symptoms; furthermore, hypomagnesemia is refractory to magnesium supplementation until PPIs are withdrawn [13]. Dietary magnesium is largely absorbed in the small bowel and kidneys play a highly efficient role in its conservation, with 3% of filtered magnesium lost in the urine, most of which is reabsorbed in the thick ascending limb of the loop of Henley. Mechanisms by which the intestinal and renal handling of magnesium is affected by PPIs are unknown. PPI- induced hypochlorhydria is postulated to impair magnesium solubilization and absorption in the small intestine, ultimately depleting its body stores [14]. Variant alleles of active magnesium transport ion channel TRPM 6/7 are associated with subtle mal absorption or persistent leak through the kidneys, which may be further aggravated by PPIs [15]. This might explain why only a minority of PPI-treated patients develop Hypomagnesemic Hypoparathyroidism. However, the lack of any report of hypomagnesemia associated with H2-blockers does not support a mechanistic role of hypochlorhydria in PPI-induced hypomagnesemia [16,17].
Hypomagnesemic hypoparathyroidism has been reported with different PPIs, and our patient had ongoing hypomagnesemia with both omeprazole and pantoprazole. The potential to trigger a subclinical magnesium depletion or an overt deficiency status seems to be a class effect that may apply to all PPIs.16If PPI-associated hypomagnesemia is dose-related and if it can recur with re challenge remains unclear.17We underscore the need for close monitoring of blood magnesium levels during long-term PPI therapy. PPI therapy is a rare but fully reversible cause of unexplained hypoparathyroidism.
Proton pump inhibitors and risk of fractures
Concerns have been raised about the risk of fractures with acid-suppressive medications, such as proton pump inhibitors and histamine-2 receptor antagonists. In this metaanalysis of observational studies, proton pump inhibitors modestly increased the risk of hip, spine, and any-site fractures, whereas histamine-2 receptor antagonists were not associated with fracture risk. The possibility of residual confounding cannot be excluded. Further skeletal evaluation should be considered for patients who are taking proton pump inhibitors and also at risk for osteoporotic fracture.
For more Open Access Journals in Juniper Publishers please click on: https://www.crunchbase.com/organization/juniper-publishers
For more articles in Open Access Novel Approaches in Drug Designing & Development please click on: https://juniperpublishers.com/napdd/index.php
For more Open Access Journals please click on: https://juniperpublishers.com
To know more about Juniper Publishers please click on: https://juniperpublishers.business.site/
#Hypoparathyroidism#Gastrointestinal bleeding#Coronary syndrome#Juniper Publishers#open access publishers
0 notes
Last Seen Blogs
